Integrum’s technology using AI gives an above-elbow amputee unprecedented control of every finger in a bionic hand
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Pressmeddelande

Integrum’s technology using AI gives an above-elbow amputee unprecedented control of every finger in a bionic hand

Mölndal, Sweden, July 13, 2023 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the first case study of a person with above-elbow amputation obtaining unprecedented control of every finger in a bionic hand has been published in Science Translational Medicine. By combining Integrum’s OPRA Implant System and e-OPRA Implant System with revolutionary surgical and engineering advancements and AI algorithms, the user’s intentions were translated into the movement of the bionic fingers.

The scientific paper illustrates how Integrum’s technology combined with advanced reconstructive surgery and AI for the first time, made it possible for an above-elbow amputee patient to control every finger of a prosthetic hand as if it were his own. The surgery took place at the Sahlgrenska University Hospital and combined new microsurgical techniques with sophisticated implanted electrodes that provide single-finger control of a prosthetic arm as well as sensory feedback. The embedded neuromuscular sensors were connected to an electronic system via Integrum’s bone-anchored interface (OPRA Implant System and e-OPRA Implant System), and AI algorithms in the electronic system translated the user’s intentions into prosthetic finger movements.

“Integrum not only provides solutions for a more efficient mechanical connection between the body and the prosthesis, but our cutting-edge research with bidirectional communication to the body using implanted electrodes combined with AI is also raising the bar for how we can restore human function. It’s a great accomplishment based on 30 years of developing the concept, where Integrum is proud to have played a key role,” comments Rickard Brånemark, CEO of Integrum and co-author.

The study was run by a collaboration with Integrum and researchers at the Center for Bionics and Pain Research, Chalmers University of Technology, Sahlgrenska University Hospital, and the Sahlgrenska Academy at the University of Gothenburg, the Bionics Institute in Melbourne, Australia, the Istituto Ortopedico Rizzoli, Bologna, Italy, the Scuola Superiore Sant’Anna, Pisa, Italy, the K. Lisa Yang Center for Bionics, Massachusetts Institute of Technology, Cambridge, USA.

Nyheter om Integrum

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!

STÄNG X
Populär sparapp – över 500 000 nedladdningar
Många och höga externa omdömen
Högst grad av diversifiering
Perfekt för regelbundet månadssparande
KOM IGÅNG

Nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 får automatiskt 50 procent rabatt på Optis avgift i 3 månader

Om aktien Integrum

Senaste nytt